The aim of this review is to discuss the current trend of using 177Lu-PSMA therapy, including dosimetry, side effects, treatment efficacy and survival rates, while referring to the literature and examining the prospects for prostate cancer therapy with targeted alpha therapy. The gene discussed is FOLH1; the disease is prostate carcinoma.